SEC Company Response from Oyster Point Pharma, Inc. (CIK 0001720725) — Nov 12, 2020
Oyster Point Pharma, Inc. (CIK 0001720725)
Date: Nov. 12, 2020 · CIK: 0001720725 · Accession: 0001193125-20-291342
AI Filing Summary & Sentiment
File numbers found in text: 333-249881
Letter
OYSTER POINT PHARMA, INC.
202 Carnegie Center, Suite 109
Princeton, New Jersey 08540
(609) 382-9032
November 12, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: Oyster Point Pharma, Inc.
Registration Statement on Form S-3
Filed November 5, 2020
File No. 333-249881
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-249881) (the “Registration Statement”) to become effective on Monday, November 16, 2020, at 9:00 a.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes each of Divakar Gupta and Brandon Fenn of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or, in his absence, Brandon Fenn of Cooley LLP at (212) 479-6626.
In connection with this request, the Registrant acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
OYSTER POINT PHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP OYSTER POINT PHARMA, INC. 202 Carnegie Center, Suite 109 Princeton, New Jersey 08540 (609) 382-9032 November 12, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Oyster Point Pharma, Inc. Registration Statement on Form S-3 Filed November 5, 2020 File No. 333-249881 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-249881) (the “Registration Statement”) to become effective on Monday, November 16, 2020, at 9:00 a.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes each of Divakar Gupta and Brandon Fenn of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or, in his absence, Brandon Fenn of Cooley LLP at (212) 479-6626. In connection with this request, the Registrant acknowledges that: • should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, OYSTER POINT PHARMA, INC. By: /s/ Jeffrey Nau Name: Jeffrey Nau, Ph.D., M.M.S. Title: President, Chief Executive Officer and Director cc: Divakar Gupta, Cooley LLP Brandon Fenn, Cooley LLP